Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Opsens Inc T.OPS

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that can be integrated into other medical devices. The Industrial segment develops, manufactures and installs fiber optic sensing solutions for critical and demanding industrial applications. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and lesions access. It is approved for sale in the United States, European Union, Japan and Canada.


TSX:OPS - Post by User

<< Previous
Bullboard Posts
Next >>
Post by retiredcfon Feb 01, 2022 9:13am
147 Views
Post# 34384215

RBC

RBC

February 1, 2022

Outperform

Speculative Risk

TSX: OPS; CAD 1.95

Price Target CAD 4.00

Opsens Inc.

Supply agreement with Abiomed extended for another 4 years, slight positive in our view

Our view: OpSens announced a four-year extension to its current Abiomed supply agreement. Recall that the ongoing supply agreement was signed in 2019 for five years ending 2024. After today's announcement the agreement with Abiomed is extended through April 2028. We view this development as a slight positive for OpSens and believe that the agreement extension highlights the strength of the company's technology. The next major catalyst for the company is the potential approval of SavvyWire by Health Canada (May-Jun) and the USFDA (Sep-Oct).

First impression:

Extension of supply agreement with Abiomed: OpSens announced a four- year extension of its supply agreement with Abiomed to supply critical component for Abiomed’s Impella heart pump through April 2028. Recall that the ongoing supply agreement with Abiomed was signed in 2019 for five years. The contract included mutual renewal clauses and, as such, we view today's announcement on the supply agreement renewal as a slight positive. OpSens generated revenues of $8.1MM from OEMs in FY21 (~23.5% of total revenues).

Upcoming catalysts. Management, during the FQ1/22 earnings call, noted that the company was in discussions to sign a number of new contracts and expected to announce at least one contract with a major GPO in the coming months. On the regulatory approval timelines for SavvyWire, management expects approval from Health Canada in May'22-Jun'22 and a potential approval from the USFDA in the Sep'22-Oct'22 timeframe. OPS will also file a regulatory submission for SavvyWire in Europe this year. We note there are near term headwinds for OPS due to Omicron but reiterate our positive outlook on the company as procedure volumes normalize and SavvyWire receives approval in OPS's key markets (here).

SavvyWire could potentially become a new standard of care as part of the TAVR procedure. Currently, the TAVR procedure typically requires the use of an echocardiogram and pacemaker in addition to a guidewire. SavvyWire can deliver the valve and perform continuous pressure measurement simultaneously. We believe time/cost savings and efficacy benefits could allow OPS to ultimately command a 35–40%+ share of TAVR guidewire supply in its current markets (US, Canada, EMEA, and Japan). TAVR is a ~US $4B+ global market which we estimate to grow at an 11–12% CAGR to ~US $7B+ by calendar 2025, with the number of procedures increasing from our forecast of ~200K in 2020E to 300K+ in 2025E. We recently lowered the risk profile of SavvyWire following several positive developments over the last year and increased our OPS PT to 4.00 (here).


<< Previous
Bullboard Posts
Next >>